Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02KBE
|
|||
| Former ID |
DIB002589
|
|||
| Drug Name |
Ad-OC-hsvTK/valacyclovir
|
|||
| Synonyms |
Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Winship Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 1 (TK1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007778) | |||
| REF 2 | Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.